Life Science Nation Newsletter  | February 9,  2017  |  Issue 200

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Feb. 2  - Feb. 8)
Invests in Therapeutics, Medical Devices and Biotech R&D Services
Looks Early for Healthcare Products
Makes Direct Early Stage Investments in Surgical Tools, Medtech and Healthcare IT
Seeks US Medtech, Mobile Health and Consumer Health Opportunities
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
By Michael Quigley, VP of Market Research, LSN

As RESI prepares for its second landing on MaRS on April 4th, the team at Life Science Nation is proud to announce the RESI investor panel agenda. With three tracks of panel and workshop content, RESI will feature a wealth of speakers representing all categories of life science investors, from family offices to VCs and angels to big pharma. These panels are a must-see for any fundraising entrepreneur in the sector...

By Christine A. Wu, Senior Research Analyst, LSN

On April 4th, the Redefining Early Stage Investments (RESI) Conference will be held at the MaRS Discovery District for the second time. RESI is a full day partnering event that allows early-stage life science, med tech, and digital health companies meet and develop relationships with investors and strategic partners all within the heart of Canada's healthcare innovation hub...

By Cole Bunn, Senior Research Analyst, LSN

Orphan diseases present a unique opportunity for an investor as there are several advantages from a regulatory standpoint given the shorter development timeline and exclusivity possibility as well as the ability to truly impact patient's lives that have no treatment options. On the flipside, they have challenges primarily due to the size of the patient population and usually require a somewhat unique business model and marketing strategy to be a viable opportunity.

In our first and largest RESI conference of 2017, held for the third time at the Marines Memorial Club and Hotel during the JP Morgan healthcare week, a varied group of investors explore some of these challenges and opportunities with funding and commercializing rare disease drugs and share their firsthand experience in this space...